Pazelliptine

Drug Profile

Pazelliptine

Alternative Names: BD 40; NSC 303565; NSC 3274714D; SR 95225A

Latest Information Update: 08 Dec 1994

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Sanofi-Synthelabo
  • Class Antineoplastics; Antiretrovirals; Indoles; Isoquinolines; Small molecules
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 08 Dec 1994 Discontinued-II for Cancer in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top